Lexicon Pharmaceuticals, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $209.97M
  • PE -1
  • Debt $100.30M
  • Cash $66.66M
  • EV $243.61M
  • FCF -$179.81M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$200.40M
EBIT-$197.12M
ROE-137%
ROA-66%
FCF-$179.81M
Equity$145.95M
Growth Stability1
PE-1.05
PB1.44
P/FCF-1.17
P/S6.76
Price/Cash0.32
Debt/Equity0.69
Debt/FCF-0.56
Net Margins-645%
Gross Margins98%
Op. Margins-634%
Earnings CAGR-0%
Sales Growth YoY4K%
Sales Growth QoQ1K%
Sales CAGR-44%
FCF CAGR-0%
Equity CAGR-1%
Earnings Stability0
Earnings Growth YoY-32%
Earnings Growth QoQ-48%
Sales CAGR 5Y-47%
Equity CAGR 5Y16%
Earnings CAGR 3Y729%
Sales CAGR 3Y729%
Equity CAGR 3Y35%
Market Cap$209.97M
Revenue$31.08M
Assets$298.42M
Total Debt$100.30M
Cash$66.66M
Shares Outstanding320.03M
EV243.61M
Earnings Score6%
Moat Score0%
Safety Score63%
Final Score23%
Working Capital200.95M
Current Ratio5.44
Gross Profit$30.47M
Shares Growth 3y35%
Equity Growth QoQ-18%
Equity Growth YoY57%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

SEC Filings

Direct access to Lexicon Pharmaceuticals, Inc. (LXRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Lexicon Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Lexicon Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%
Stability 0%
loading chart...

Lexicon Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Lexicon Pharmaceuticals, Inc..

= -$1.8B
012345678910TV
fcf-$180M-$180M-$179M-$179M-$179M-$179M-$178M-$178M-$178M-$178M-$178M-$1.8B
DCF-$163M-$148M-$135M-$122M-$111M-$101M-$91M-$83M-$75M-$68M-$685M
Value-$1.8B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-4%-170%-143%-191%40%-244%-29K%-73K%-15K%-645%-645%
ROA--29%-31%-36%34%-23%-64%-52%-75%-66%-66%
ROE--90%-248%457%111%-37%-77%-87%-190%-137%-137%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--0.67-1.43-1.692.28-0.09-0.01-0.54-0.61-0.56-0.56
Debt over Equity0.380.755.1-9.512.220.080.010.411.070.690.69
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth--36%8%-30%410%-93%-99%-53%766%2K%-47%
Earnings YoY growth-3K%-9%-7%-208%-145%50%16%74%13%-
Equity YoY growth--45%-67%-151%-543%34%-27%3%-21%57%16%
FCF YoY growth--196%6%-20%-176%-226%-38%2%80%11%-